BioLineRx Ltd.: financial analysis
Ratios worked out from 10 fiscal years of BioLineRx Ltd.'s statements, compared with 665 companies in Biotechnology.
BioLineRx Ltd. scorecard#
Passes 2 of the 11 checks that could be worked out: strongest in financial health (1 of 4), weakest in profitability (0 of 4). Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year0.00 vs -0.01Diluted EPS 0.00 in fiscal 2025 against -0.01 the year before (report's currency).
- ✓Net income higher than five years earlier-$2 M-$2 M in fiscal 2025 against -$30 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 4
- ✗Profitable in the newest year-$2 MNet income -$2 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-872.0%-872.0% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-12.8%-12.8% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 4
- ✓Short-term assets cover short-term liabilities1.9×Current ratio 1.95 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-8.0×Operating income -8.0 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-13.78Z-score -13.78 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year105.8%Diluted shares up 105.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
What the 2025 statements show#
Each line is an observation with its numbers, not a judgement of the company.
Worth a look
- Net loss of $2 million, the 11th loss-making year in a row.
- Free cash flow was negative: -$8 million.
- The share count rose 105.8% in the year.
- Operating income covers the interest bill only -8.0 times.
Piotroski F-score
Nine yes/no tests of whether the company's finances improved in the year. One point each.
- Made a profitno
- Operations brought in cashno
- Return on assets roseyes
- Cash from operations exceeds profitno
- Long-term debt fell against assetsnot on file
- Current ratio roseyes
- No new shares issuedno
- Gross margin roseyes
- Asset turnover roseno
Altman Z-score
A 1968 formula that weighs five balance-sheet ratios. It was built on listed manufacturers and says less about other kinds of company.
| Part | Ratio | Weight | Points |
|---|---|---|---|
| Working capital to assets | 0.28 | × 1.2 | 0.34 |
| Retained earnings to assets | -9.80 | × 1.4 | -13.73 |
| Operating income to assets | -0.25 | × 3.3 | -0.83 |
| Market value to liabilities | 0.69 | × 0.6 | 0.41 |
| Revenue to assets | 0.03 | × 1 | 0.03 |
Profitability#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 80.5% | 68.0% | 23.1% | — | — | 74.8% | 55% | |
| Operating margin | -872.0% | -70.5% | — | — | — | -60.5% | 2% | |
| Net margin | -172.0% | -31.9% | — | — | — | -68.9% | 33% | |
| Return on equity | -12.8% | -69.1% | -189.2% | -42.0% | -60.0% | -61.0% | 84% | |
| Return on assets | -5.1% | -17.9% | -86.4% | -31.6% | -42.0% | -44.4% | 85% |
Growth#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | 502.9% | — | — | — | 15.8% | — |
Financial strength#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Interest cover | -8.04× | -2.24× | — | — | — | -22.77× | 68% | |
| Current ratio | 1.95× | 1.76× | — | — | — | 4.39× | 21% | |
| Equity share of assets | 44.5% | 34.6% | 20.7% | 66.6% | 83.7% | 64.7% | 34% |
Cash#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Free cash flow | $-8 M | $-44 M | $-23 M | $-26 M | $-24 M | $-40 M | 76% | |
| Free cash flow margin | -685.6% | -151.8% | -473.5% | — | — | -61.5% | 7% | |
| Capital spending share of revenue | 1.7% | 0.2% | 2.5% | — | — | 1.7% | — |
Efficiency#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Asset turnover | 0.03× | 0.56× | 0.07× | — | — | 0.26× | 8% |
How each figure is worked out#
- Gross margin
- Gross profit as a share of revenue.
- Operating margin
- Operating income as a share of revenue.
- Net margin
- Net income as a share of revenue.
- Return on equity
- Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
- Return on assets
- Net income as a share of total assets (average of the year).
- Revenue growth
- Revenue against the year before.
- Interest cover
- Operating income divided by the interest paid on debt.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Free cash flow
- Cash from operations less capital spending.
- Free cash flow margin
- Free cash flow as a share of revenue.
- Capital spending share of revenue
- Capital spending as a share of revenue.
- Change in share count
- Diluted shares against the year before. Negative: fewer shares.
- Asset turnover
- Revenue divided by total assets (average of the year).
Source: BioLineRx Ltd.'s statements: annual reports filed with the SEC. Arithmetic on reported figures, in US dollars; nothing is estimated. A figure is blank when a line it needs is not in the statements on file, and left out when the result cannot be right (a margin from next to no revenue). "Ahead of" is the share of the 665 companies in Biotechnology that BioLineRx Ltd. is better than on that figure, using each company's newest fiscal year; yields use today's market value. Medians for every industry · Back to BioLineRx Ltd.